Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Page: 95

Published Date: 01 Apr 2021

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Dendritic Cell Cancer Vaccine Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Dendritic Cell Cancer Vaccine Immunotherapy size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Dendritic Cell Cancer Vaccine Immunotherapy market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Dendritic Cell Cancer Vaccine Immunotherapy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Provenge
    Apceden
    CreaVax
    Others

Market segment by Application, can be divided into
    Pediatrics
    Adults

Market segment by players, this report covers
    Lineage Cell Therapeutics
    AVAX Technologies
    DCPrime
    Gradalis
    Heat Biologics
    ImmunoCellular Therapeutics
    Immunicum
    MolecuVax
    Northwest Biotherapeutics
    Pique Therapeutics
    Regeneus
    Tessa Therapeutics
    Vaccinogen
    XEME Biopharma

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Dendritic Cell Cancer Vaccine Immunotherapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Dendritic Cell Cancer Vaccine Immunotherapy, with revenue, gross margin and global market share of Dendritic Cell Cancer Vaccine Immunotherapy from 2019 to 2021.
Chapter 3, the Dendritic Cell Cancer Vaccine Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Dendritic Cell Cancer Vaccine Immunotherapy market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Dendritic Cell Cancer Vaccine Immunotherapy research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Dendritic Cell Cancer Vaccine Immunotherapy
    1.2 Classification of Dendritic Cell Cancer Vaccine Immunotherapy by Type
        1.2.1 Overview: Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type in 2020
        1.2.3 Provenge
        1.2.4 Apceden
        1.2.5 CreaVax
        1.2.6 Others
    1.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market by Application
        1.3.1 Overview: Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Pediatrics
        1.3.3 Adults
    1.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size & Forecast
    1.5 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast by Region
        1.5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region, (2016-2021)
        1.5.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2016-2026)
        1.5.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2016-2026)
        1.5.6 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
        1.6.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
        1.6.3 Dendritic Cell Cancer Vaccine Immunotherapy Trends Analysis

2 Company Profiles
    2.1 Lineage Cell Therapeutics
        2.1.1 Lineage Cell Therapeutics Details
        2.1.2 Lineage Cell Therapeutics Major Business
        2.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.1.4 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Lineage Cell Therapeutics Recent Developments and Future Plans
    2.2 AVAX Technologies
        2.2.1 AVAX Technologies Details
        2.2.2 AVAX Technologies Major Business
        2.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.2.4 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 AVAX Technologies Recent Developments and Future Plans
    2.3 DCPrime
        2.3.1 DCPrime Details
        2.3.2 DCPrime Major Business
        2.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.3.4 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 DCPrime Recent Developments and Future Plans
    2.4 Gradalis
        2.4.1 Gradalis Details
        2.4.2 Gradalis Major Business
        2.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.4.4 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Gradalis Recent Developments and Future Plans
    2.5 Heat Biologics
        2.5.1 Heat Biologics Details
        2.5.2 Heat Biologics Major Business
        2.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.5.4 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Heat Biologics Recent Developments and Future Plans
    2.6 ImmunoCellular Therapeutics
        2.6.1 ImmunoCellular Therapeutics Details
        2.6.2 ImmunoCellular Therapeutics Major Business
        2.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.6.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 ImmunoCellular Therapeutics Recent Developments and Future Plans
    2.7 Immunicum
        2.7.1 Immunicum Details
        2.7.2 Immunicum Major Business
        2.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.7.4 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 Immunicum Recent Developments and Future Plans
    2.8 MolecuVax
        2.8.1 MolecuVax Details
        2.8.2 MolecuVax Major Business
        2.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.8.4 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 MolecuVax Recent Developments and Future Plans
    2.9 Northwest Biotherapeutics
        2.9.1 Northwest Biotherapeutics Details
        2.9.2 Northwest Biotherapeutics Major Business
        2.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.9.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Northwest Biotherapeutics Recent Developments and Future Plans
    2.10 Pique Therapeutics
        2.10.1 Pique Therapeutics Details
        2.10.2 Pique Therapeutics Major Business
        2.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.10.4 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 Pique Therapeutics Recent Developments and Future Plans
    2.11 Regeneus
        2.11.1 Regeneus Details
        2.11.2 Regeneus Major Business
        2.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.11.4 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 Regeneus Recent Developments and Future Plans
    2.12 Tessa Therapeutics
        2.12.1 Tessa Therapeutics Details
        2.12.2 Tessa Therapeutics Major Business
        2.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.12.4 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 Tessa Therapeutics Recent Developments and Future Plans
    2.13 Vaccinogen
        2.13.1 Vaccinogen Details
        2.13.2 Vaccinogen Major Business
        2.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.13.4 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.13.5 Vaccinogen Recent Developments and Future Plans
    2.14 XEME Biopharma
        2.14.1 XEME Biopharma Details
        2.14.2 XEME Biopharma Major Business
        2.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.14.4 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2021)
        2.14.5 XEME Biopharma Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Dendritic Cell Cancer Vaccine Immunotherapy Players Market Share
        3.2.2 Top 10 Dendritic Cell Cancer Vaccine Immunotherapy Players Market Share
        3.2.3 Market Competition Trend
    3.3 Dendritic Cell Cancer Vaccine Immunotherapy Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Market Share by Type (2016-2021)
    4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Forecast by Type (2021-2026)

5 Market Size Segment by Application
    5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2016-2021)
    5.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application
    6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2026)
    6.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2026)
    6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        6.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2026)
        6.3.2 United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        6.3.3 Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        6.3.4 Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application
    7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2026)
    7.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2026)
    7.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        7.3.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2026)
        7.3.2 Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        7.3.3 France Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        7.3.5 Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        7.3.6 Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2026)
    8.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2026)
    8.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region
        8.3.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Region (2016-2026)
        8.3.2 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        8.3.3 Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        8.3.4 South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        8.3.5 India Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        8.3.7 Australia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application
    9.1 South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2026)
    9.2 South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2026)
    9.3 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        9.3.1 South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2026)
        9.3.2 Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        9.3.3 Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2026)
    10.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2026)
    10.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        10.3.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2026)
        10.3.2 Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)
        10.3.4 UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
    Table 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
    Table 3. Global Market Dendritic Cell Cancer Vaccine Immunotherapy Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
    Table 4. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) by Region (2016-2021)
    Table 5. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region (2021-2026)
    Table 6. Lineage Cell Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 7. Lineage Cell Therapeutics Major Business
    Table 8. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 9. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 10. AVAX Technologies Corporate Information, Head Office, and Major Competitors
    Table 11. AVAX Technologies Major Business
    Table 12. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 13. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 14. DCPrime Corporate Information, Head Office, and Major Competitors
    Table 15. DCPrime Major Business
    Table 16. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 17. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 18. Gradalis Corporate Information, Head Office, and Major Competitors
    Table 19. Gradalis Major Business
    Table 20. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 21. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 22. Heat Biologics Corporate Information, Head Office, and Major Competitors
    Table 23. Heat Biologics Major Business
    Table 24. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 25. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 26. ImmunoCellular Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 27. ImmunoCellular Therapeutics Major Business
    Table 28. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 29. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 30. Immunicum Corporate Information, Head Office, and Major Competitors
    Table 31. Immunicum Major Business
    Table 32. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 33. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 34. MolecuVax Corporate Information, Head Office, and Major Competitors
    Table 35. MolecuVax Major Business
    Table 36. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 37. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 38. Northwest Biotherapeutics Corporate Information, Head Office, and Major Competitors
    Table 39. Northwest Biotherapeutics Major Business
    Table 40. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 41. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 42. Pique Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 43. Pique Therapeutics Major Business
    Table 44. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 45. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 46. Regeneus Corporate Information, Head Office, and Major Competitors
    Table 47. Regeneus Major Business
    Table 48. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 49. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 50. Tessa Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 51. Tessa Therapeutics Major Business
    Table 52. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 53. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 54. Vaccinogen Corporate Information, Head Office, and Major Competitors
    Table 55. Vaccinogen Major Business
    Table 56. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 57. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 58. XEME Biopharma Corporate Information, Head Office, and Major Competitors
    Table 59. XEME Biopharma Major Business
    Table 60. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 61. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 62. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) by Players (2019-2021)
    Table 63. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Players (2019-2021)
    Table 64. Breakdown of Dendritic Cell Cancer Vaccine Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 65. Dendritic Cell Cancer Vaccine Immunotherapy Players Head Office, Products and Services Provided
    Table 66. Dendritic Cell Cancer Vaccine Immunotherapy Mergers & Acquisitions in the Past Five Years
    Table 67. Dendritic Cell Cancer Vaccine Immunotherapy New Entrants and Expansion Plans
    Table 68. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) by Type (2016-2021)
    Table 69. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Type (2016-2021)
    Table 70. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Forecast by Type (2021-2026)
    Table 71. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2021)
    Table 72. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Forecast by Application (2021-2026)
    Table 73. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2021) & (USD Million)
    Table 74. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2021-2026) & (USD Million)
    Table 75. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2021) & (USD Million)
    Table 76. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2021-2026) & (USD Million)
    Table 77. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2021) & (USD Million)
    Table 78. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2021-2026) & (USD Million)
    Table 79. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2021) & (USD Million)
    Table 80. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2021-2026) & (USD Million)
    Table 81. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2021) & (USD Million)
    Table 82. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2021-2026) & (USD Million)
    Table 83. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2021) & (USD Million)
    Table 84. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2021-2026) & (USD Million)
    Table 85. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2021) & (USD Million)
    Table 86. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2021-2026) & (USD Million)
    Table 87. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2021) & (USD Million)
    Table 88. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2021-2026) & (USD Million)
    Table 89. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Region (2016-2021) & (USD Million)
    Table 90. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Region (2021-2026) & (USD Million)
    Table 91. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2021) & (USD Million)
    Table 92. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2021-2026) & (USD Million)
    Table 93. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2021) & (USD Million)
    Table 94. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2021-2026) & (USD Million)
    Table 95. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2021) & (USD Million)
    Table 96. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2021-2026) & (USD Million)
    Table 97. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2016-2021) & (USD Million)
    Table 98. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Type (2021-2026) & (USD Million)
    Table 99. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2016-2021) & (USD Million)
    Table 100. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Application (2021-2026) & (USD Million)
    Table 101. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2016-2021) & (USD Million)
    Table 102. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Country (2021-2026) & (USD Million)
List of Figures
    Figure 1. Dendritic Cell Cancer Vaccine Immunotherapy Picture
    Figure 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type in 2020
    Figure 3. Provenge
    Figure 4. Apceden
    Figure 5. CreaVax
    Figure 6. Others
    Figure 7. Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application in 2020
    Figure 8. Pediatrics Picture
    Figure 9. Adults Picture
    Figure 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (USD Million): 2020 VS 2021 VS 2026
    Figure 11. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Forecast (2016-2026) & (USD Million)
    Figure 12. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region (2016-2026)
    Figure 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region in 2020
    Figure 14. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 15. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 16. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 17. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 18. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 19. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
    Figure 20. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
    Figure 21. Dendritic Cell Cancer Vaccine Immunotherapy Market Trends
    Figure 22. Lineage Cell Therapeutics Recent Developments and Future Plans
    Figure 23. AVAX Technologies Recent Developments and Future Plans
    Figure 24. DCPrime Recent Developments and Future Plans
    Figure 25. Gradalis Recent Developments and Future Plans
    Figure 26. Heat Biologics Recent Developments and Future Plans
    Figure 27. ImmunoCellular Therapeutics Recent Developments and Future Plans
    Figure 28. Immunicum Recent Developments and Future Plans
    Figure 29. MolecuVax Recent Developments and Future Plans
    Figure 30. Northwest Biotherapeutics Recent Developments and Future Plans
    Figure 31. Pique Therapeutics Recent Developments and Future Plans
    Figure 32. Regeneus Recent Developments and Future Plans
    Figure 33. Tessa Therapeutics Recent Developments and Future Plans
    Figure 34. Vaccinogen Recent Developments and Future Plans
    Figure 35. XEME Biopharma Recent Developments and Future Plans
    Figure 36. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Players in 2020
    Figure 37. Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    Figure 38. Global Top 3 Players Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share in 2020
    Figure 39. Global Top 10 Players Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share in 2020
    Figure 40. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
    Figure 41. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Type in 2020
    Figure 42. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Type (2021-2026)
    Figure 43. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Application in 2020
    Figure 44. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Application (2021-2026)
    Figure 45. North America Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Type (2016-2026)
    Figure 46. North America Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Application (2016-2026)
    Figure 47. North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Country (2016-2026)
    Figure 48. United States Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 49. Canada Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 50. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 51. Europe Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Type (2016-2026)
    Figure 52. Europe Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Application (2016-2026)
    Figure 53. Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Country (2016-2026)
    Figure 54. Germany Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 55. France Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 56. United Kingdom Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 57. Russia Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 58. Italy Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 59. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Type (2016-2026)
    Figure 60. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Application (2016-2026)
    Figure 61. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region (2016-2026)
    Figure 62. China Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 63. Japan Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 64. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 65. India Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 66. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 67. Australia Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 68. South America Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Type (2016-2026)
    Figure 69. South America Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Application (2016-2026)
    Figure 70. South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Country (2016-2026)
    Figure 71. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 72. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 73. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Type (2016-2026)
    Figure 74. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Sales Market Share by Application (2016-2026)
    Figure 75. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Country (2016-2026)
    Figure 76. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 77. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 78. UAE Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 79. Methodology
    Figure 80. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Lineage Cell Therapeutics
AVAX Technologies
DCPrime
Gradalis
Heat Biologics
ImmunoCellular Therapeutics
Immunicum
MolecuVax
Northwest Biotherapeutics
Pique Therapeutics
Regeneus
Tessa Therapeutics
Vaccinogen
XEME Biopharma

Related Reports

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

date 14 Jan 2022

date Pharma & Healthcare

The Dendritic Cell Cancer Vaccine Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2023-2029

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2023-2029

date 23 Jan 2023

date Pharma & Healthcare

The global Dendritic Cell Cancer Vaccine Immunotherapy market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 10 Jan 2023

date Pharma & Healthcare

Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 04 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Dendritic Cell Cancer Vaccine Immunotherapy market size was valued at USD 640 million in 2023 and is forecast to a readjusted size of USD 1220.9 million by 2030 with a CAGR of 9.7% during review period.

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2024-2030

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2024-2030

date 29 Feb 2024

date Pharma & Healthcare

The global Dendritic Cell Cancer Vaccine Immunotherapy market size is expected to reach $ 1220.9 million by 2030, rising at a market growth of 9.7% CAGR during the forecast period (2024-2030).

Product Tags

dendritic cell cancer vaccine immunotherapy

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>